DTE proteins, or ‘difficult-to-express’ proteins are a common hurdle for researchers in the lab. Due to difficulty with correct protein folding and general protein synthesis success, coronavirus proteins find themselves with the deserved label of DTE proteins. The first coronavirus pandemic, SARS-CoV, had many researchers struggling with the synthesis of many of its proteins including SARS-CoV membrane protein, nucleocapsid proteins, RBD proteins, S1 and S2 proteins. LifeSensors had extensive experience with synthesizing DTE proteins even two decades ago. With our SUMO-fusion technology, we were able to assist the globe by providing a bulk amount of SARS-CoV proteins in the early 2000s.
SARS-CoV-2, while close in homology to its SARS-CoV cousin, still has its own individual DTE protein characteristics. This makes it difficult to create SARS-CoV-2 proteins efficiently while remaining cost-effective. Over the past several months, LifeSensors has developed new methods on how to synthesize these new coronavirus proteins to provide scientific and diagnostic assistance. When undergoing diagnostic and medicinal clinical studies, large quantities of antigens are typically required. With only small quantities available, research is delayed while waiting for the necessary SARS-CoV-2 antigens.
LifeSensors can provide both BULK quantities of SARS-CoV-2 proteins such as nucleocapsid, RBD, S1, and S2 while remaining cost-effective. There is no need to wait to continue with life-saving research, nor is there a need to go over budget. If you require large amounts of SARS-CoV-2 proteins, contact us today.